Multiple sclerosis treatment preferences
Research type
Research Study
Full title
Treatment preferences among patients with multiple sclerosis and neurologists
IRAS ID
214934
Contact name
Michael Edwards
Contact email
Sponsor organisation
Biogen
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
This study is designed to collect information about patient preference towards relapsing remitting multiple sclerosis (RRMS) treatments. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system. The most common form of MS is RRMS which represents 85% of all new cases.
This study will be carried out in two separate phases. The first phase will consist of qualitative pilots with 24 MS patients (evenly represented from the US, UK and Germany which will be identified and recruited via physician sites) and 24 neurologists (evenly represented from the US, UK and Germany and which will be identified and recruited from online panels and/or research database). Interviews will last approximately 60 minutes and will be carried out over the phone.
The second phase of this study will consist in a 20 minute quantitative research with both MS patients and physicians. Patients in the US, UK, and Germany will be identified and recruited via ≤ 30 physician sites per country (N=474 patients) and through online panels/research databases (N=225 patients) and invited to complete a web survey designed to understand their treatment preferences using a Discrete-choice experiment (DCE).
Physicians in the US, UK, and Germany (N=450) will be recruited from online panels/research databases to complete a web survey designed to understand their treatment preferences using a DCE.
The DCE is a survey approach designed to assess respondents’ willingness to accept trade-offs among hypothetical treatment profiles described by treatment attributes of varying levels. This study will be conducted according to best practice guidelines published by the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
The study will last approximately 1-2 years which will include enrolment and data collection for both the Qualitative Pilots and the Quantitative Research with patients and physicians.
REC name
East of England - Essex Research Ethics Committee
REC reference
16/EE/0457
Date of REC Opinion
28 Nov 2016
REC opinion
Further Information Favourable Opinion